Vemurafenib-induced eccrine squamous syringometaplasia.
Dermatology
; 226(4): 362-4, 2013.
Article
de En
| MEDLINE
| ID: mdl-23860306
ABSTRACT
We report herein a patient treated with vemurafenib for a stage IV melanoma who developed an eruption related to eccrine squamous syringometaplasia (ESS). This entity is a well-described side effect of cytostatic therapies used for malignant neoplasia and is clinically characterized by a symmetric cutaneous eruption composed of papules and vesicles preferentially located on fold and intertriginous areas. It is histologically defined by a squamous metaplasia of eccrine ductal epithelium. ESS represents another skin eruption to be added to the list of cutaneous adverse events associated with vemurafenib, a selective BRAF inhibitor used to treat patients with metastatic melanoma harboring the V600E mutation. The discussion focuses on the pathogenesis of ESS secondary to vemurafenib and on alternative diagnoses.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs cutanées
/
Sulfonamides
/
Toxidermies
/
Glandes eccrines
/
Cellules épithéliales
/
Indoles
/
Mélanome
/
Antinéoplasiques
Limites:
Adult
/
Humans
/
Male
Langue:
En
Journal:
Dermatology
Sujet du journal:
DERMATOLOGIA
Année:
2013
Type de document:
Article
Pays d'affiliation:
France